Drug Profile
Research programme: bone marrow transplant therapeutics - CellCyte Genetics
Alternative Names: CCG-T50; Stem cell therapeutics - CellCyte GeneticsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Department of Veterans Affairs
- Class
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bone marrow disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-marrow-disorders in USA (Parenteral)
- 01 Oct 2005 Preclinical trials in Bone marrow disorders in USA (Parenteral)